These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30747340)

  • 21. Tyrosine kinase inhibitor therapy in chronic myeloid leukemia: update on key adverse events.
    Carneiro BA; Kaplan JB; Giles FJ
    Expert Rev Hematol; 2015 Aug; 8(4):457-79. PubMed ID: 25938861
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tyrosine-kinase inhibitors and patient-reported outcomes in chronic myeloid leukemia: a systematic review.
    Efficace F; Cardoni A; Cottone F; Vignetti M; Mandelli F
    Leuk Res; 2013 Feb; 37(2):206-13. PubMed ID: 23177797
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.
    Ali MA
    Mol Diagn Ther; 2016 Aug; 20(4):315-33. PubMed ID: 27220498
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Generic imatinib in the treatment of chronic myeloid leukemia: two years' experience in Latvia.
    Lejniece S; Udre I; Rivkina A
    Exp Oncol; 2017 Jul; 39(2):151-154. PubMed ID: 29483494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BCR-ABL inhibitors in chronic myeloid leukemia: process chemistry and biochemical profile.
    Leonetti F; Stefanachi A; Nicolotti O; Catto M; Pisani L; Cellamare S; Carotti A
    Curr Med Chem; 2011; 18(19):2943-59. PubMed ID: 21651486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cognitive behavioral therapy positively affects fatigue in patients with multiple sclerosis: Results of a randomized controlled trial.
    van den Akker LE; Beckerman H; Collette EH; Twisk JW; Bleijenberg G; Dekker J; Knoop H; de Groot V;
    Mult Scler; 2017 Oct; 23(11):1542-1553. PubMed ID: 28528567
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitors.
    Gugliotta G; Castagnetti F; Fogli M; Cavo M; Baccarani M; Rosti G
    Expert Rev Hematol; 2013 Oct; 6(5):563-74. PubMed ID: 24083631
    [TBL] [Abstract][Full Text] [Related]  

  • 28. How has treatment changed for blast phase chronic myeloid leukemia patients in the tyrosine kinase inhibitor era? A review of efficacy and safety.
    Perrone S; Massaro F; Alimena G; Breccia M
    Expert Opin Pharmacother; 2016 Aug; 17(11):1517-26. PubMed ID: 27231757
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Young age and high cost are associated with future preference for stopping tyrosine kinase inhibitor therapy in Chinese with chronic myeloid leukemia.
    Jiang Q; Liu ZC; Zhang SX; Gale RP
    J Cancer Res Clin Oncol; 2016 Jul; 142(7):1539-47. PubMed ID: 27085529
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study protocol of the TIRED study: a randomised controlled trial comparing either graded exercise therapy for severe fatigue or cognitive behaviour therapy with usual care in patients with incurable cancer.
    Poort H; Verhagen CA; Peters ME; Goedendorp MM; Donders AR; Hopman MT; Nijhuis-van der Sanden MW; Berends T; Bleijenberg G; Knoop H
    BMC Cancer; 2017 Jan; 17(1):81. PubMed ID: 28129746
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives.
    Massimino M; Stella S; Tirrò E; Pennisi MS; Vitale SR; Puma A; Romano C; DI Gregorio S; Tomarchio C; DI Raimondo F; Manzella L
    Anticancer Res; 2020 May; 40(5):2457-2465. PubMed ID: 32366389
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cognitive behavioral therapy or graded exercise therapy compared with usual care for severe fatigue in patients with advanced cancer during treatment: a randomized controlled trial.
    Poort H; Peters MEWJ; van der Graaf WTA; Nieuwkerk PT; van de Wouw AJ; Nijhuis-van der Sanden MWG; Bleijenberg G; Verhagen CAHHVM; Knoop H
    Ann Oncol; 2020 Jan; 31(1):115-122. PubMed ID: 31912784
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison.
    Hyland KA; Eisel SL; Hoogland AI; Root JC; Bowles K; James B; Nelson AM; Booth-Jones M; Jacobsen PB; Ahles TA; Jim HSL; Gonzalez BD
    Leuk Lymphoma; 2023 Feb; 64(2):415-423. PubMed ID: 36476293
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ponatinib in chronic myeloid leukemia (CML): Consensus on patient treatment and management from a European expert panel.
    Müller MC; Cervantes F; Hjorth-Hansen H; Janssen JJWM; Milojkovic D; Rea D; Rosti G
    Crit Rev Oncol Hematol; 2017 Dec; 120():52-59. PubMed ID: 29198338
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CR-LAAO antileukemic effect against Bcr-Abl(+) cells is mediated by apoptosis and hydrogen peroxide.
    Burin SM; Ghisla S; Ouchida AT; Aissa AF; Coelho MG; Costa TR; Marsola AP; Pinto-Simões B; Antunes LM; Curti C; Sampaio SV; de Castro FA
    Int J Biol Macromol; 2016 May; 86():309-20. PubMed ID: 26812110
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence of BCR-ABL T315I Mutation in Malaysian Patients with Imatinib-Resistant Chronic Myeloid Leukemia.
    Mat Yusoff Y; Abu Seman Z; Othman N; Kamaluddin NR; Esa E; Zulkiply NA; Abdullah J; Zakaria Z
    Asian Pac J Cancer Prev; 2018 Dec; 19(12):3317-3320. PubMed ID: 30583336
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bosutinib: a second-generation tyrosine kinase inhibitor for chronic myelogenous leukemia.
    Stansfield L; Hughes TE; Walsh-Chocolaad TL
    Ann Pharmacother; 2013 Dec; 47(12):1703-11. PubMed ID: 24396109
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cardiovascular, pulmonary, and metabolic toxicities complicating tyrosine kinase inhibitor therapy in chronic myeloid leukemia: Strategies for monitoring, detecting, and managing.
    Medeiros BC; Possick J; Fradley M
    Blood Rev; 2018 Jul; 32(4):289-299. PubMed ID: 29454474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring chronic myelogenous leukemia in the age of tyrosine kinase inhibitors.
    Radich JP; Oehler V
    J Natl Compr Canc Netw; 2007 May; 5(5):497-504. PubMed ID: 17509253
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BCR-ABL PCR testing in chronic myelogenous leukemia: molecular diagnosis for targeted cancer therapy and monitoring.
    Luu MH; Press RD
    Expert Rev Mol Diagn; 2013 Sep; 13(7):749-62. PubMed ID: 24063401
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.